• IGFBP3 binds insulin growth factors 1 and 2 (IGF-1, IGF-2) and acts as the main carrier of both factors through the bloodstream [R].
  • Higher levels of IGFBP-3 in the body (T) [R]
  • Decreased levels of IGFBP-3 in the body (G) [R]

The Minor "G" allele is associated with:

  • Premenopausal breast cancer (BCA) in subjects using oral contraception [R].
  • Prostate cancer [R].
  • Esophageal squamous cell carcinoma (ESCC) [R].
  • Increased risk of developing Breast cancer [R].
  • Larger tumors in subjects for the cancers listed above [R] [R].
  • Tumors that respond poorly to chemoradiotherapy [R].
  • A decrease in ASMI in elderly subjects with this polymorphism [R]. ASMI leads to increased muscle and bone disabilities [R].
  • Less favorable outcome to treatment with recombinant growth hormone in subjects with Turner syndrome [R].
  • Gastric carcinoma if the polymorphism is paired with a polymorphism in the IGF2 gene [R].
  • Decreased risk of Bladder cancer and colorectal cancer [R] [R].
  • Renal cell carcinoma [R]
  • Increased levels of LDL cholesterol in the body, which in turn increases risk of obesity [R].

The Major "T" allele is associated with:

  • Decreased risk of developing breast cancer, prostate, ESCC, breast, and renal forms of cancer [R] [R] [R] [R] [R].
  • Increased survival rate after developing these cancers with proper treatment [R] [R] [R].
  • Reduced risk of developing muscle or bone disabilities during aging [R].
  • Possible increased risk of developing bladder cancer and colorectal cancer [R] [R].
  • Reduced LDL cholesterol levels in the body, which could reduce risks of obesity [R].


Parent Gene: IGFBP3

Importance: 4
Less common allele: G = 47%
More common allele: T = 53%
My Genotype: Log In